Core Points - The company, JieTe Bio, announced a change in its continuous supervision sponsor representatives due to personnel changes at the sponsoring institution [2] - Guolian Minsheng Securities, which has merged with Minsheng Securities, is now responsible for the continuous supervision of JieTe Bio's 2022 convertible bond issuance project [2] - The new appointed representatives, Chen Sijie and Shang Shulei, will take over the duties from the previous representatives, Li Dongmao and Zhang Chunhui, to ensure the continuity of supervision [2]

Core Logic - The company has over 20 years of experience in the biological laboratory consumables sector, focusing on biological culture and liquid handling, with leading technical strength and a comprehensive product matrix. The company is expected to maintain rapid growth and become a global leader in laboratory consumables [1] Group 1: Overseas Market - The company is leveraging an ODM model to penetrate the global biological laboratory consumables supply chain, establishing stable partnerships with international leaders like VWR and Thermo Fisher, and exporting products to over 70 countries. The company is enhancing its brand image as "reliable quality" and "outstanding cost performance" [2] - In 2024, the company's revenue from overseas self-owned brands is expected to increase by 46.07%, with overseas revenue accounting for 18.89% of total income. This indicates a successful transition from OEM to self-owned brand, capturing more value in the international laboratory consumables supply chain [2] Group 2: Domestic Market - The company is positioned to capitalize on the opportunity for import substitution in the current international trade environment, with a strong first-mover advantage in producing disposable plastic consumables for biological laboratories. The company plans to expand its sales network by establishing 12 offices in China in 2024, enhancing service responsiveness [3] - The company is also targeting industrial clients through high-quality cell factories, serving sectors like biopharmaceuticals and vaccine production. In 2024, sales from cell factory products are projected to grow by approximately 28.55%, indicating strong growth momentum [3] Group 3: Product Development and Cost Efficiency - The company is focused on developing high-end products such as liquid culture media and cell culture bags, while optimizing its product structure. It is also improving manufacturing processes and introducing automation to steadily reduce unit manufacturing costs [4] - The establishment of an intelligent manufacturing base will support the automation upgrade of production lines and the implementation of an intelligent warehousing system, which is expected to enhance order delivery efficiency and support global business demands [4] Group 4: Financial Projections - The company forecasts revenues of 652 million yuan, 772 million yuan, and 919 million yuan for 2025-2027, with year-on-year growth rates of 16.7%, 18.3%, and 19.1% respectively. The projected net profits for the same period are 98 million yuan, 118 million yuan, and 145 million yuan, with growth rates of 35.3%, 20.6%, and 23.2% respectively [4]

| 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-062 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 关于变更持续督导保荐代表人的公告 特此公告。 广州洁特生物过滤股份有限公司 2025 年 9 月 26 日 1 附：陈思捷先生、尚书磊先生简历 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）于近日收到保荐机构 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"）《关于变更持 续督导保荐代表人的函》。 民生证券股份有限公司（以下简称"民生证券"）为公司 2022 年向不特定对 象发行可转换公司债券的保荐机构，李东茂先生和张春晖先生为公司持续督导保 荐代表人，法定持续督导期限至 2024 年 12 月 31 日。国联民生证券股份有限公 司已完成对民生证券的合并，承销保荐业务整合进入全资子公司国联民生承销保 荐，故国联民生承销保荐现为公司 2022 年度向不特定对象发行可转换公 ...

Investment Rating - The investment rating for the company is "Buy" [2] Core Views - The report highlights that the company has over 20 years of experience in the biological laboratory consumables sector, focusing on biological culture and liquid handling, with leading technical strength and a comprehensive product matrix. The company is expected to maintain rapid growth as its influence in overseas markets increases and both domestic industrial and research markets expand [3][4][5] Summary by Sections 1. Overseas Market - The company has entered the global biological laboratory consumables supply chain through an ODM model, establishing stable partnerships with international leaders like VWR and Thermo Fisher. The company has built a reputation for "reliable quality" and "outstanding cost performance," with overseas self-brand revenue increasing by 46.07% year-on-year in 2024, accounting for 18.89% of total revenue [4][14] 2. Domestic Market - The company is well-positioned to capitalize on the opportunity for import substitution in the current international trade climate. As one of the earliest producers of disposable plastic consumables in China, the company is expanding its sales network and has established 12 offices domestically in 2024. The sales of its cell factory products are expected to grow by approximately 28.55% year-on-year [5][49][53] 3. Product High-Endization and Smart Manufacturing - The company is focused on developing high-end products such as liquid culture media and cell culture bags while optimizing production processes to reduce manufacturing costs. The establishment of an intelligent manufacturing base is expected to enhance order delivery efficiency and support global business needs [6][15] 4. Financial Forecast and Investment Recommendation - The company is projected to achieve revenues of 652 million yuan, 772 million yuan, and 919 million yuan from 2025 to 2027, with year-on-year growth rates of 16.7%, 18.3%, and 19.1% respectively. The net profit attributable to the parent company is expected to be 98 million yuan, 118 million yuan, and 145 million yuan during the same period, with corresponding growth rates of 35.3%, 20.6%, and 23.2% [6][8][20]

Group 1 - The company, Guangzhou Jet Biofiltration Co., Ltd., will hold a half-year performance briefing on September 30, 2025, from 11:00 to 12:00 [2][5] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [3][4] - Investors can submit questions for the briefing from September 23 to September 29, 2025, through the Roadshow Center website or via the company's email [6]

重要内容提示： 上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-061 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 投资者可于 2025 年 09 月 23 日（星期二）至 09 月 29 日（星期一）16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 jetzqb@jetbiofil.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 广州洁特生物过滤股份有限公司（以下简称"公司"）已于 2025 年 08 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公 ...

Group 1 - The company has elected Ms. Dannie Yuan as the employee representative director of the fourth board of directors, effective from the date of the employee representative assembly's approval until the end of the board's term [1][2][4] - The election of the employee representative director complies with relevant laws and regulations, ensuring that the number of directors who are also senior management and employee representatives does not exceed half of the total number of directors [2][4] - Ms. Dannie Yuan holds 21,000 shares in the company and has not faced any penalties from regulatory authorities, nor does she fall under any disqualifications as per the Company Law or the company's articles of association [4] Group 2 - The company held its second extraordinary general meeting of shareholders on September 16, 2025, with all procedures and attendance complying with the Company Law and the company's articles of association [5][7][11] - All resolutions presented at the meeting were approved, including amendments to the company's articles of association and the cancellation of the supervisory board [9][10][11] - The meeting was witnessed by legal representatives from Guangdong Guangxin Junda Law Firm, confirming the legality and validity of the meeting's proceedings and resolutions [11]

Core Viewpoint - The company announced the election of a staff representative director to its board, reflecting its commitment to employee representation in governance [1] Group 1 - The company held a staff representative meeting to discuss and approve the election of a staff representative director [1] - Dannie Yuan was elected as the staff representative director for the fourth board of directors, with her term starting from the approval date of the staff representative meeting until the end of the fourth board's term [1]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-060 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司董事会 2025 年 9 月 17 日 1 附件：Dannie Yuan 女士简历 Dannie Yuan，女，1993 年出生，美国国籍，美国加利佛尼亚州州立大学洛 杉矶分校本科学历，市场管理学及经济学专业。2017 年 3 月至 2018 年 3 月在 TAG Energy Co.,Ltd.担任销售经理，2018 年 5 月至今在公司国际销售部、市场部、 招商部任职，2020 年 9 月至今在公司担任董事。 Dannie Yuan 女士为公司控股股东、实际控制人之一袁建华先生之女，直接 持有公司股份 21,000 股，未受过中国证监会及其他有关部门的处罚和证券交易 所惩戒，不存在作为失信被执行人的情形，不存在《公司法》《公司章程》中规 定的不得担任董事的情形。 广州洁特生物过滤股份有限公司 选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏 ...

广东广信君达律师事务所 关于 广州洁特生物过滤股份有限公司 2025 年第二次临时股东会的 法律意见书 二〇二五年九月 地址：广东省广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 29 层、10 层、11 层（01-04 单元、10-11 单元） 邮编（P.C）：510623 电话（Tel）：020-37181333 传真（Fax）：020-37181388 网址（Website）：www.etrlawfirm.com 法律意见书 广东广信君达律师事务所 关于广州洁特生物过滤股份有限公司 2025 年第二次临时股东会的法律意见书 （2025）粤广信君达律委字第 1878-2 号 致：广州洁特生物过滤股份有限公司 广东广信君达律师事务所（以下简称"本所"）接受广州洁特生物过滤股份有 限公司（以下简称"公司"）的委托，指派律师（以下简称"本所律师"）出席公司 2025 年第二次临时股东会（以下简称"本次股东会"），并获授权依据《中华人 民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》《上市 公司股东会规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 和《广州洁特生物过滤股 ...